presence of BRAF GA. Multiple examples of clinical efficacy of treatment with either anti-BRAF alone or in combination with anti-MEK targeted therapy in the BRAF GA cohort will be presented. Conclusions: GA in BRAF are widely distributed in BT with base substitutions primary seen in high grade tumors and BRAF fusions in low grade tumors. Both BRAF base substitutions and fusions can be successfully targeted with anti-BRAF and anti-MEK targeted therapies. The development of biomarker-driven basket type clinical trials for all types of BT that feature BRAF GA appears warranted.
Malignant Peripheral Nerve Sheath Tumors Are Negative for Estrogen Receptor β by Immunohistochemistry
Dylan Coss, Jennifer Ju, Anne M Mills. University of Virginia, Charlottesville, VA. Background: Malignant peripheral nerve sheath tumors (MPNSTs) are rare, highly aggressive malignancies of the peripheral nervous system with a poor prognosis and few available treatment modalities. They are more common in patients with neurofibromatosis type 1, wherein the lifetime risk of developing an MPNST approaches 15%. 5-and 10-year survival rates for MPNSTs remain at a dismal 34% and 23%, respectively, in part due to lack of efficacious chemotherapeutic regimens. Surgery is currently the primary treatment for MPNST though complete resection is difficult due to aggressive invasion and metastases. In search for new treatment options for MPNST, studies have found that the selective estrogen receptor modulator (SERM) tamoxifen inhibits the proliferation and survival of MPNST cells in vitro, however the mechanism for this treatment is yet to be described. In this study, we sought to characterize the immunophenotypic profile of MPNSTs for estrogen receptor (ER) expression to elucidate this mechanism. Design: The institutional archives were searched for all cases of MPNST diagnosed from 2002 through 2015. 16 individual cases with adequate material were identified for evaluation. The original H&E slides were reviewed prior to staining to confirm diagnosis and ensure adequate tumor volume. Immunohistochemical staining for ER-β was performed on each case using a selective antibody (ACA 301B Biocare). Results of the staining were separately evaluated by 3 observers. Results: Of the 16 cases evaluated, 9 tumors were from men and 7 were from women. Mean age of patient at resection was 45.8 years (range: 10-82). All tumors had high grade spindled morphology with robust mitotic activity, consistent with the diagnosis of MPSNT. Immunostaining performed on the original work-up revealed positivity for S100 (10/16) and CD56 (7/8) with negative reactivity for additional melanocytic markers (HMB45: 0/3, MelanA: 0/5) and muscle markers (desmin: 0/7, SMA 0/13). The 16 cases evaluated were all found to be negative for nuclear and cytoplasmic ER-β staining by immunohistochemical evaluation. Conclusions: Despite evidence that SERMs such as tamoxifen inhibit the proliferation of MPNSTs there is little data to show whether or not this inhibition involves the estrogen receptor. Our current study shows that MPNST tumor cells do not express the ER-β subunit, suggesting that tamoxifen exerts its inhibitory effect in an ER-β independent mechanism. Further studies are required to better illustrate the exact role SERMs play in MPNST inhibition.
Gliomas of Children and Young Adults-BRAFV600E Mutation
Anupurva Dutta, Hetakshi Kurani, Aliasgar Moiyadi, Prakash Shetty, Jayant Sastri, Tejpal Gupta, Rakesh Jalali, Sridhar Epari. TMC, Mumbai, India. Background: BRAFV600E mutation is relatively common in non-pilocytic low grade gliomas(LGG) in pediatric and young adults. However, it is also reportedin pilocytic astrocytoma(PCA) and high grade gliomas(HGG). This is a study to evaluate the frequency of BRAFV600E in non-ependymal glial tumors of children and young adults. Design: Formalin fixed and paraffin embedded tissue of all non-ependymal glial tumours diagnosed in patients aged ≤30 years during 2011-2013 were evaluated for BRAFV600E by sequencing and subsequently correlated with different clinicopathological features using appropriate statistical methods. Results: A total of 136 LGG and 64 HGG formed the study sample with age ranging from 2-30 years and M:F=1.7:1. Most common location for LGG was cerebral hemisphere(n:52; 38.2%), followed by posterior fossa(n: 42 cases, which included 34 cases in cerebellum, 2 in cerebellar peduncle and in 6 no specific site known), dicephalon(n:23 cases-sellar/suprasellar:10; thalamus:6, hypothalamus:4, optic chiasma:2 & 3rd ventricle:1), optic nerve:7, spine:7, lateral ventricle:3 and 2 in brainstem. PCA(n:83; classic:61; atypical:22) was the commonest histological subtype; while others included infiltrating low grade astrocytoma(n:13); pilomyxoid astrocytoma(n:1); pleomorphic xanthoastrocytoma(PXA)(n:9 -low grade:4; with anaplasia [aPXA]:5), oligodendroglial tumours(n:14), astrocytomas-not otherwise specified(n:8), glioneuronal tumours(GNT, n:7) and subependymal giant cell astrocytoma(n:1).Most common location for HGG was cerebral hemisphere(n:57;85%), followed by posterior fossa(n:5, 3 in cerebellum & 2 in cerebellar peduncle); pineal/ third ventricle:1 and spine:1.Histological spectrum included glioblastoma(GBM) (n:46;including GBM with oligodendroglioma component(GBM-O):6, age group -1-6yrs:4; 7-14yrs:17; 15-20yrs:6 & 21-30yrs:19) , anaplastic astroctyoma (aA)(n:4; age group -7-14yrs:1; 15-20yrs:1; 21-30yrs:2), anaplastic oligoastrocytoma(aOA) (n:6, age group -7-14yrs:1 & 21-30yrs:5), anaplastic oligodendroglioma(aO)(n:8, age group -18-20yrs:3 & 21-30yrs:5) . 111 LGG and 39 HGG cases respectively yielded interpretable BRAFV600E results. It was seen in 13 (11.7%) LGG and 5 (12.8%) HGG respectively. 9 were PCA, 2 each were aPXA and GBM and one each of GNT, aO and infiltrating glial tumour respectively. Presence of BRAFV600E did not show any statistical correlation for any of the histological subtype, age of the patient and location of the tumour. Conclusions: Thirteen LGG cases (11.7%) exhibited the BRAFV600E mutation, more commonly in PXAs (28.6%) but it can also be seen in other histological subtypes including infiltrating gliomas and HGG. Jordan M Gales, Ruta Yardi, Lara Jehi, Richard Prayson. Cleveland Clinic, Cleveland, OH. Background: Hippocampal sclerosis is the most commonly observed pathology associated with medically intractable temporal lobe epilepsy. There have been many attempts at identifying subtypes of observed neuronal loss and gliosis in hippocampal sclerosis. The consensus classification scheme proposed by the International League against Epilepsy (ILAE) in 2013 attempted to standardize classification. Previous series have implicated that hippocampal sclerosis subtypes could be predictive of seizure history and outcome. In particular, it has been suggested that the CA1 predominant subtype of hippocampal sclerosis (ILAE type 2) is associated with a worse prognosis as compared with the more commonly encountered Type 1 lesions. This study retrospectively examines features of the ILAE type 2 subtype. Design: Cases of pathologically confirmed hippocampal sclerosis diagnosed between January 2000 through December 2012 (n= 349) were reviewed and 38 cases (11%) were identified who had a CA1 predominant pattern of hippocampal sclerosis (ILAE type II). The clinicopathologic features of these cases were reviewed. Results: Thirty eight individuals (median age of 33 with a median disease duration of 20 years, and a median pre-surgery seizure frequency of 5 per month) were followed for a median duration of 4.5 years post-operatively. The most commonly observed seizure type within this cohort was complex partial seizures. Sixty percent had a history of generalized seizures. Six individuals had a confirmed history of status epilepticus. Eighty-four percent of cases had an identifiable epilepsy risk factor including 45% with a history of childhood febrile seizure. Of those individuals with an ipsilateral temporal lobe specimen submitted for pathology, 71% were found to have focal cortical dysplasia, most commonly resembling ILAE subtypes Ic and Ib patterns morphologically. Twenty four individuals (63%) were seizure free (Engel class 1) at the time of last follow up. The average duration until seizure recurrence in the remaining patients was 7.8 months with a median Engel class 2 surgical outcome. Conclusions: Patients with ILAE type 2 hippocampal sclerosis often have longstanding seizures prior to surgery (median 20 years) and a history of identifiable epilepsy risk factors in most cases (84%). The majority (71%) were associated with adjacent focal cortical dysplasia. Postoperative seizure freedom (63% was on par with rates reported in the literature for Type 1 subtypes (60-80% range).
CA1-Predominant Hippocampal Sclerosis in Medically Refractory Temporal Lobe Epilepsy

Absence of CMV Components in High Grade Gliomas by Real-Time PCR, Immunohistochemistry and Chromogenic In-Situ Hybridization
Gunes Guner, Fausto Rodriguez, Jessica Hicks, Xiaobu Ye, Stuart Grossman, Peter Burger, Charles G Eberhart, Angelo M De Marzo, Ravit Boger, Matthias Holdhoff. Johns Hopkins Medical Institutions, Baltimore, MD. Background: Several studies suggested a common pathogenetic role for human cytomegalovirus (CMV) in high grade gliomas (HGG). This led to the use of antiviral agents and CMV-targeted vaccines in some patients. However, evidence exists both for and against CMV presence in HGG. Design: Eighteen newly diagnosed HGG patients (mean age:55,M/F:9/9,6 anaplastic astrocytomas,2 gliosarcomas,10 glioblastomas) were enrolled. FFPE tumors were assessed for CMV DNA by real-time quantitative PCR(n=8). Plasma CMV DNA copy number was noted at baseline and follow-up visits. Serum CMV IgG avidity index testing was used to assess prior CMV exposure. Tumors from this cohort and an additional 19 patients underwent chromogenic in-situ hybridization(CISH) and IHC. We analytically validated 2 CISH assays for FFPE against 2 different segments of CMV DNA(probes from Advanced Cell Diagnostics-ACD) with the RNAScope 2.0 detection kit. IHC assays for corresponding CMV proteins pp65(VP-C422/Vector Lab.), and VP CMV IE1(MAB810/Millipore) were validated and performed on FFPE tissues. Positive controls were human fibroblasts infected with human CMV, and negative controls were uninfected CMV-PCR negative cells. Other positive controls were from patients with clinically detected CMV in biopsies. IHC for pp65 and IE1 was also done on 70 other HGGs (24 pediatric,46 adult) using a tissue microarray(TMA). Results: CMV-PCR was negative in DNA from FFPE tissues(n=8). In standard sections from these patients, and an additional set of cases(n=26 total), IHC was negative for both antibodies in all cases tested(25/25) and no definitive positive staining was seen with either CISH probe(n=26). All TMA cores were negative by both IHC assays. IgG avidity index test was positive(0.55-0.82) in 8/15 cases, consistent with rates in the general population.CMV DNA in plasma was detected in 3 patients at baseline and 1 other patient at follow-up(4/38 samples), 34 were negative. Conclusions: 5 independent CMV assays using multiple modalities (PCR,CISH,IHC) were all negative in HGG samples, providing strong evidence for CMV's absence high grade gliomas. A centrally coordinated multi-center investigation using blinded controls and patient samples should be conducted before more patients are treated with anti-CMV drugs or vaccines. Jen-Fan Hang, Chih-Yi Hsu, Donald M-T Ho. Taipei Veterans General Hospital, Taipei, Taiwan. Background: Subependymal giant cell astrocytoma (SEGA) is a benign brain tumor associated with tuberous sclerosis complex, which most commonly occurs around foramen of Monro. Diagnosis of SEGA is usually straightforward when clinicoradiological picture is suggestive. However, due to presence of large epithelioid to spindle tumor cells with conspicuous pleomorphism and occasional atypical features such as endothelial proliferation and tumor necrosis, there is a potential for misinterpretation of SEGAs as other high-grade brain tumors. Immunohistochemically, SEGAs frequently show co-expression of glial and neuronal markers. Nevertheless, most of these markers stain in a patchy and focal fashion and can be positive in a variety of brain tumors. Therefore, they have a limited role as diagnostic tools. The aim of this study was to investigate the diagnostic utility of thyroid transcription factor-1 (TTF-1) in distinguishing SEGAs from other histologic and locational mimickers. Design: A total of 26 SEGA specimens from 22 patients were removed during the period of 1995 to 2013. All the original H&E slides were retrieved for detailed microscopic review. Twenty-four corresponding paraffin blocks with sufficient tissue were subjected to tissue microarray construction. For comparison, tissue microarrays of a selection of mimickers, including histologic mimickers (3 pleomorphic xanthoastrocytomas, 151 astrocytomas including 20 gemistiocytic astrocytomas, and 24 gangliogliomas) as well as tumors predominantly occurring at the ventricular system (50 ependymomas, 7 subependymomas, and 19 neurocytomas), were used. Immunohistochemical stains for TTF-1 (clone 8G7G3/1 and SPT24) were performed and the staining intensity was recorded. Results: In microscopic review, all cases are composed of large epithelioid cells and spindle cells. Psammomatous calcification was noted in 10 (38%), chicken wire vessels in 15 (58%), perivascular halos in 11 (42%), angiomatous pattern in 7 (27%), lymphocytic infiltration in 7 (27%), mast cell infiltration in 4 (15%), xanthoma cell aggregation in 3 (12%), and tumor necrosis in 4 (15%) SEGAs. Immunohistochemical stains for TTF-1 were positive in all 24 SEGAs, while negative for all pleomorphic xanthoastrocytomas, astrocytomas, gangliogliomas, ependymomas, and subependymomas. Neurocytomas were positive for TTF-1 in 4 (21%) cases using clone 8G7G3/1 and in 9 (47%) using clone SPT24. Conclusions: TTF-1 is a useful marker in distinguishing SEGAs from other histologic and locational mimickers except neurocytomas. Margaret P Holmes, Diana Bell, Rajesh Singh, Raja Luthra, Russell Broaddus, Michael T Tetzlaff, Bita Esmaeli. University of Texas MD Anderson Cancer Center, Houston, TX. Background: Ocular melanomas are classified based on the anatomic site from which they arise, including conjunctival and uveal subtypes. Conjunctival melanoma accounts for 5-10% of all ocular melanomas and is associated with a high rate of recurrence and metastases. Conjunctival melanoma can either arise from a nevus, from primary acquired melanosis or without an identifiable precursor lesion. Although the etiology of conjunctival melanoma is not well understood, previous studies have detected mutations in BRAF in a significant number of these tumors. Since BRAF mutations are also detected in cutaneous melanomas but not in uveal melanomas, it seems that conjunctival melanomas are more closely genetically linked to cutaneous melanomas. Design: To further test this relationship, a genetic analysis of 21 conjunctival melanomas was conducted. Results: After DNA was extracted, PCR-based sequencing was performed using a next generation sequencing (NGS) platform to detect somatic mutations in the coding sequence of a total of 409 genes. BRAF mutations were identified in 7 of 21 (33%) conjunctival melanomas, which is a significant proportion of the tumors tested, and these results support previous studies that have demonstrated a similar molecular relationship. Conclusions: A significant proportion of conjunctival melanomas are associated with BRAF mutations, similar to cutaneous melanomas. This concept raises the question of whether conjunctival melanomas should have a similar treatment course as cutaneous subtypes, and understanding how best to classify these tumors is critical for optimal patient outcomes. Miguel A Idoate, Inigo Arana, Adriana Hogeboom, Jose I Echeveste, Alvaro LopezJaneiro, Ricardo Diez-Valle, Luis D Mejias Sosa, Francisco Guillen. University of Navarra, Pamplona, Navarra, Spain. Background: Glioblastomas (GB) possess several relevant mechanisms of immune escape. The expression of programmed death ligand 1 (PD-L1) with its corresponding T cell receptor (PD1) are now considered central to the immunological control of cancer. The M2 macrophages actively support glioma growth by the release of factors that suppress immunity. The clinical antineoplastic effect of a novel class of immune modulatory agents depends on both the expression and the interaction of these immune mechanisms. There are currently few published studies concerning the role and relevance of immune modulation in GB. Design: Sixty-eight clinically and molecularly characterized primary GB were studied. An immunohistochemical study against CD8 (clone C8/144B), PD1 (clone NAT105), PD-L1 (clone SP142), CD16 (clone 2H7, macrophage) and CD163 (clone MRQ-26, M2 macrophages) was obtained. A semi-quantitative assessment of the intratumoral cell density was performed by three observers in a blinded manner. In the case of CD16 and CD163, immunostained cells were graded and differentiated in microglial and macrophage phenotypes. A statistical analysis using Pearson's Chi-square test and simple lineal regression was performed as well as a survival analysis using Cox regression test. Results: The CD8 cellular density was variable with an intratumoral and perivascular arrangement in 97% (0-1:50%; 2-3:50%) of GB. A membranous PD1 expression was observed in lymphoid cells in 72% of GB (0-1:66%; 2-3:34%). This parameter correlated significantly with CD8 (p<0.0001). A cytoplasmic PD-L1 expression was observed in 74% of GB (0-1:74%; 2-3:26%). The CD16 immunostained cells had a microglial (30%) or macrophage (70%) phenotype. The CD163 (M2) expression correlated significantly with CD16 (p<0.0001). A coexistent intense expression (≥2) of PD-1, PD-L1 and CD8 was observed in 15% of GB; coexistent expression of PD1, PD-L1, CD8 and CD163 was present in 9% of GB. The high expression of PD1 and PD-L1 correlated significantly with a poorer overall survival in the Cox regression test -PD1 (p=0.025 [1.53 IC95(1.05-2.21)]; PD-L1 (p=0.049 [1.43 IC95(1.00-2.04)-]. Conclusions: A dual mechanism of inhibition of immune response exists associated to both CD8/PD-1/PDL1 and anti-inflammatory M2 macrophage effect in GB, which are expressed intensely in a subgroup of GB. The high expression of PD1/PD-L1 inhibition mechanism correlates with a poorer overall survival in GB.
Thyroid Transcription Factor-1 Is a Useful Maker in Distinguishing Subependymal Giant Cell Astrocytoma and Other Mimickers
Conjunctival Melanomas Harbor BRAF Mutations: Confirmatory Exome Sequencing Analysis of 409 Cancer-Related Genes
The High Expression of Programmed Death-1 Ligand-1 (PD-L1) and Its Receptor PD1 Correlates with a Poorer Prognosis In Glioblastomas
Intracranial Fibrosarcomas: Clinicopathologic Characteristics in 9 Patients
Bryan Iorgulescu. Brigham and Women's Hospital, Boston, MA. Background: Intracranial fibrosarcomas are rare lesions often associated with prior radiotherapy, and whose paucity have limited the study of their outcomes. Design: Patients who underwent treatment for central nervous system tumors at UCSF, UCLA, or UCSD since 1985 were retrospectively queried for biopsy-proven diagnosis of fibrosarcoma. Patient demographics, tumor characteristics, treatment, and survival outcomes were examined. Results: The query identified 9 patients with biopsy-proven intracranial fibrosarcomas, diagnosed at a median age of 44 yrs (range 6-72). Fibrosarcomas were located supratentorially, except for a fibrosarcoma within the sella turcica and one fibrosarcoma within the posterior fossa. Four patients underwent treatment for previous CNS malignancies. All 9 patients underwent surgical resection, only 2 patients recieved radiotherapy (54.9 -69 Gy), and one patient recieved ifosfamide and epirubicin. There was evidence of local recurrence in 3 patients at a median of 2 months following resection (range 1.8 -216 months), 6 patients died at a median of 7.9 months (range 2.5 -77.5) post-surgery, and the other 3 were censored at last follow-up (median of 19.5 yrs after surgery, range 2.4-28.3 yrs). Conclusions: Intracranial fibrosarcomas represent a rare but serious complication of radiotherapy for CNS malignancies, that can mimic more benign meningiomas on radiographic imaging but may portend poor prognosis despite maximal therapy.
Is All Inflammation within Temporal Artery Biopsies Temporal Arteritis?
Liwei Jia, Marta Couce, Mark L Cohen. Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, OH. Background: Peak incidence of giant cell arteritis is during the 8 th decade, affecting patients with frequent comorbidities who are especially prone to adverse effects of corticosteroid therapy. Perivascular inflammation involving small periadventitial vessels is not uncommon in otherwise normal temporal artery biopsies (TAB). As cranial ischemic events in these patients are as frequent as in patients with transmural temporal arteritis, it has been recommended that both forms of inflammation be treated with corticosteroids. We sought to determine whether such patients are at increased risk for temporal arteritis-like adverse events compared with age-matched controls devoid of inflammatory infiltrates. Design: TABs without temporal arteritic damage accessioned between 2002 and 2012 were reviewed for inflammation (>15 perivascular lymphocytes) involving small vessels and/or temporal artery adventitia. Records were reviewed for demographics, corticosteroid therapy, and adverse events (stroke, cardiovascular events, blindness, and death). Biopsies matched for age and post-TAB follow-up but devoid of inflammation were similarly reviewed. Results: 278/343 (81%) of TABs were negative for giant cell arteritis. Inflammation involving small vessels and/or temporal artery adventitia was present in 56 cases (20%). 16 cases were excluded due to lack of follow up or availability of age-matched controls. With a mean follow up of 5 years (range 1 -11 years), 6/40 (15%) of patients developed stroke, cardiovascular events or died, compared with 7/39 (18%) of age matched controls. Conclusions: Our results demonstrate that patients with inflammation involving small vessels or temporal artery adventitia only are not at increased risk for temporal arteritislike adverse events, and suggest that the risks of protracted corticosteroid therapy in this elderly population likely exceed any potential benefits. We advise against diagnosing vasculitis in the absence of temporal arteritic damage.
Infratentorial Ependymomas: Clinicopathological and Immunohistochemical Characterization
Gordana Juric-Sekhar, Tatsuya Ozawa, Jason K Barber, Eric C Holland. University of Washington, Seattle, WA; Fred Hutchinson Cancer Reseach Center, Seattle, WA; Universitiy of Washington, Seattle, WA. Background: Ependymomas (EPNs) are tumors of glial origin arising along the entire neuroaxis. Recent data suggests that these tumors display biological characteristics according to their location. Insights regarding the molecular alterations found in infratentorial (IT) EPNs have recently forthcoming; however, key molecular events in their pathogenesis are still debated. Design: To further elucidate the pathogenesis of IT-EPNs, we studied a cohort of 55 patients with IT-EPNs (16 PF-EPNs and 39 SC-EPNs) by using immunohistochemistry (RelA, YAP1, phosphorylated YAP1-pYAP1, Olig2, CD44 and vimentin). Each tumor was scored with respect to the nuclear versus cytoplasmic immunoreactivity for RelA expression, and the percentage of positive tumor nuclei (YAP1, pYAP1, and Olig2, respectively) and the percentage of membranous/cytoplasmic immunoreactivity (CD44 and vimentin, respectively) using a 4-tiered scoring system including 0-no staining, 1-<33% immunopositivity, 2-34-66% immunopositivity and 3->67% of immunopositivity.
Results: All IT-EPNs displayed RelA cytoplasmic expression, but no nuclear expression. YAP1 and pYAP1 nuclear expression was identified in all IT-EPNs. Immunopositivity scored as 2 was found in 2/16 (12.5% for both markers) PF and in 10/39 (25.6% for YAP1) and 7/39 (17.9% for pYAP1) SC-EPNs, whilst immunopositivity scored as 3 was found in 14/16 (87% for both markers) PF and in 29/39 (74.4% for YAP1) and 32/39 (82.1% for pYAP1) SC-EPNs. Olig2 expression was seen in 8/16 (50.0%) of PF-EPNs, and in 26/39 (66.7%) SC-EPNs with a score of 1. The expression of CD44 was identified in 15/16 (93.7%) PF-EPNs and 37/39 (94.9%) SC-EPNs of various levels of expression, including score 1 in 6/16 (37.5%) PF-EPNs and 18/39 (46.1%) SC-EPNs, score 2 in 6/16 (37.5%) PF-EPNs and 17/39 (43.7%) SC-EPNs, and score 3 in 3/16 (18.7%) PF-EPNs and 2/39 (5.1%) SC-EPNs. Immunoreactivity for vimentin was found in all IT-EPNs with predominant score 2 in PF-EPNs (11/16, 68.7% versus score 1 in 1/16, 6.3% versus score 3 in 4/16, 25.0%) and predominant score 3 in SCEPNs (34/39, 87.2%). Conclusions: This study indicates that the molecular background of IT-EPNs is complex. The transcriptional co-activator YAP1 in association with expression of CD44 (cancer stem cell marker) may play a role in their pathogenesis. In addition, the expression of vimentin can subclassify these tumors as mesenchymal similar to molecular signature reported to glioblastoma.
Reclassification of Mixed Oligoastrocytic Tumors Including Glioblastoma with Oligodendroglioma Component by Genetics Integrated Diagnosis
Seong-Ik Kim, Yujin Kim, Sung-Hye Park. Seoul National University Hospital, Seoul, Republic of Korea. Background: Mixed gliomas are defined as tumors composed of a mixture of two distinct neoplastic cell types; astrocytic and oligodendroglial cells. However, in situ molecular genetics can subclassify into either oligodendroglioma or astrocytoma. Astrocytic tumors (A) have ATRX mutation and oligodendroglioma (O) has isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. Therefore, these mixed entities are destined to disappear from WHO classification. This study was designed to figure out the feasibility of molecular genetics-integrated diagnoses of mixed gliomas and to find out prognostic value of new classification. Design: 58 cases of mixed OA (29) and GBMO (29) were retrieved from the pathology archives of Seoul national university hospital from 2009 to 2014. We reclassified them according to the molecular genetic studies and immunohistochemical properties, such as IDH1/2 mutation, ATRX mutation, and 1p/19q codeletion, using immunohistochemical study, direct sequencing and fluorescence in situ hybridization. Finally 58 cases were reclassified into 9 distinct subgroups, which are diffuse astrocytoma (DA) with IDH mutation, DA with IDH wild type, anaplastic astrocytoma (AA) with IDH mutation, AA with IDH wild type, O with IDH mutation, anaplastic O with IDH mutation, GBM with IDH wild type, and GBM with IDH mutation. Overall survival was assessed and compared them by Kaplan Meier survival analysis. Results: We could reclassify mixed OA into either A or O. Especially, 29 GBMOs could reclassify into 16 GBMs with IDH wild type, 10 GBMs with IDH mutation, and three AOs with IDH mutation and 1p/19q codeletion. The overall survival was significantly different among these new groups (p=0.000). The order of better overall survival was O and AO, AA IDH mutation, AA with IDH wild type and GBM with IDH mutation and GBM with IDH wild type. The younger patients showed statistically better survival than older patients (cut off: <45 years old) (p=0.013). Conclusions: Our studies highly suggested that genetics-integrated diagnoses were much more relevant to the patients' prognosis than the former morphology only-based diagnoses. The status of IDH and ATRX mutation and 1p/19q codeletion and patients' age were powerful diagnostic, prognostic and predictive factors.
Utility of Whole Genome Single Nucleotide Polymorphism Microarray (SNPM) and Targeted Somatic Mutations Analysis in the Evaluation of Adult Brain Tumors
Ravindra Kolhe, Alka Chaubey, Barbara R DuPont, WonSok Lee, Ashis K Mondal, Amyn Rojiani. Georgia Regents University, Augusta, GA; Greenwood Genetic Center, Greenwood, SC. Background: The majority of adult brain tumors lend themselves to fairly accurate histological diagnoses given an adequate biopsy. Despite this some tumors display highly variable clinical outcomes which are discordant with histology based predictions. Certain subsets of WHO grade 2 or 3 gliomas, present conflicting and/or ambiguous features that preclude a definitive consensus diagnosis on morphology alone. These limitations combined with interobserver variability in histologic assessment have made it crucial to identify clinically relevant markers that can be accurately and reliably determined. The goal of the current study is to investigate a select panel of these molecular changes on SNPM platform. Design: Tumor samples from 10 archived, histologically diagnosed adult brain tumor cases ( Fig.1) were selected for molecular testing as follows: P53 IHC, IDHR132H IHC, 1p/19q FISH, EGFR amplification. The whole genome SNPM was performed on the DNA isolated from FFPE specimens following manufacturer's protocol & raw data was analyzed in CHAS 3.0 software (OncoScanⓇ assay, Affymetrix, Inc). This platform consists of 274,000 probes including 74 somatic mutations from 9 genes (BRAF, KRAS, EGFR, IDH1, IDH2, PTEN, PIK3CA, NRAS and TP53) . An evidence based algorithm (Fig.2. ) was designed for SNPM data interpretation & molecular classifications of these gliomas. Results: Application of an evidence based customized algorithm yielded molecular diagnoses obtained with high confidence (log2 ratio) on the SNPM platform ( Fig.3 ) These data correlated conclusively (100%) with histologic grade & subtype of adult brain tumors.as well as with FISH/IHC findings (Fig 1& 2) .
Conclusions:
While we recognize that this is a very limited cohort, our results highlight the value of using high resolution molecular data derived from a small FFPE sample (10ng DNA), delivered at a much reduced cost when compared with traditional techniques. This powerful technology will facilitate the classification, diagnosis and grading of histologically challenging adult brain tumors, based on tumor biology criteria, potentially correlating more closely with clinical behavior and overall outcome. Background: Routinely used methods for processing and reviewing tissue samples using standard light microscopy have not changed for over a century. They provide high-quality images but can involve time-frames of hours or even weeks, especially in preparation of complex CNS tissue. Slide-free methods for rapid tissue histological analysis can drastically shorten pathology assessment turn-around times and can reduce cost. Design: MUSE (microscopy with UV surface excitation) exploits the shallow penetration of UV light to excite only the most superficial tissue elements. The cut surface of unsectioned tissues can be stained within seconds to provide familiar contrast. The method is non-destructive, and eliminates requirement for fixation, processing, or standard sectioning. It requires no lasers, confocal, multiphoton or optical coherence tomography optics. In this study we compare diagnostic accuracy of MUSE images analysis versus standard processing in a setting of surgical and autopsy neuropathology, with a focus on diagnosis and grading of primary brain tumors (n=15). Results: MUSE samples from fresh (or fixed) tissues stained with rhodamine and Hoechst can generate high-resolution fluorescence images that can be converted in real time from fluorescence to H&E-like brightfield appearance for ease of interpretation. This sample-sparing method has potential to provide novel appreciation of cancer biology, to ensure availability of tissue from small biopsies for molecular analyses, and to enable histology in low-resource environments. Some tissue components can be more easily visualized using MUSE compatible stains than with H&E. We have found that pathological features were highly comparable between MUSE and light microscopy in all examined neoplastic and non-neoplastic CNS specimens. Topographical information from portions of the sample below the plane of the cut surface can yield additional insights, especially valuable when analyzing complex neuroanatomical structures. Conclusions: We have developed a new form of optical microscopy that generates diagnostic-quality histological images from fresh or fixed, unsectioned tissue, with high resolution, and describe its application to neuropathology specimens. We anticipate that there could be widespread adoption in clinical and research settings, as well as in low resource environments.
Utility of PIT-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas
Julieann Lee, Melike Pekmezci, Arie Perry, Tarik Tihan. University of California San Francisco, San Francisco, CA. Background: Clinically non-functioning pituitary adenomas lack symptoms of hormone overexpression and account for approximately one third of all pituitary adenomas. This group can be further divided into silent adenomas with hormone immunoreactive tumor, and null cell adenomas (traditionally defined as hormone immunonegative). The additional criterion of null cell adenomas being immunonegative for transcription factors of adenohypophyseal differentiation has increasingly made null cell adenoma a diagnosis of exclusion. Pituitary specific transcription factor 1, Pit-1, promotes differentiation of adenohypophyseal cells into lactotrophs, somatotrophs, and thyrotrophs while the steroidogenic transcription factor 1 (SF-1) promotes the gonadotroph lineage. SF-1 has demonstrated usefulness in identifying both silent gonadotrophs, and adenomas of the gonadotroph lineage that are immunonegative for FSH or LH, as distinct entities from null cell adenomas. Pit-1 immunostaining is not routinely used in the characterization of pituitary adenomas, and its utility in distinguishing adenomas of primitive differentiation from true null cell adenomas has not formally been evaluated. Design: We have identified pituitary adenomas surgically removed at our institution over a 5-year period which were negative for expression of routinely tested hormonal markers (ACTH, prolactin, growth hormone) from the Department of Pathology archives. Recurrent tumors were excluded from the study. Tumors were further tested for TSH, SF-1 and Pit-1 expression using a tissue microarray (TMA) containing 2mm cores from each tumor. Results: There were 113 cases included in the study and 89 cases had sufficient tissue to include in the TMA. Three cases showed TSH expression and were classified as silent thyroid stimulating hormone secreting adenomas. Among hormone-negative tumors, SF-1 was expressed in 46 cases (53.5%). Of the cases that were immunonegative for ACTH, prolactin, growth hormone, TSH, and SF-1, 33 study cases had sufficient tissue for further analysis. Only 2 cases (6%) were Pit-1 positive, with 31 remaining cases of null cell adenoma. Conclusions: Pit-1 immunostaining is positive in a small subset of adenomas previously classified as null cell adenomas. Therefore Pit-1 can be utilized as a second tier immunostain in cases of clinically non-functioning adenomas that are immunonegative for hormones and SF-1.
Genetic Alterations of EGFR in High Grade Gliomas and Its Prognostic Significance
Minju Lee, So Young Kang, Yeon-Lim Suh. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Background: Glioblastoma is the most common primary brain tumor with malignant behavior, and several genetic alterations were found in glioblastoma. EGFR (epidermal growth factor receptor) amplification is one of common these alterations and is frequently associated with mutation called EGFRvIII (variant III; deletion of exon 2 to 7). Many studies on EGFR have been published, but prognostic value of EGFR amplification and mutation is still debatable. Design: Sixty eight histologically confirmed primary glioblastoma patients and 12 high grade glioma other than primary glioblastoma patients who underwent tumor resection or biopsy from June, 2008 to May, 2015 at a single tertiary institute were included for this study. Immunohistochemistry was performed to evaluate EGFR overexpression with anti-EGFR monoclonal antibody which shows reaction with both wild type EGFR and EGFRvIII. EGFR expression was scored as negative (0), 1+, 2+, and 3+. FISH analysis was performed using dual color probe. Non overlapping 100 nuclei were counted, and high polysomy or gene amplification were interpreted as amplification. RNA was extracted from FFPE sections and reverse transcribed to cDNA. Using the cDNA, real-time PCR was done with primers specific for the EGFRvIII and EGFR wild type. Additionally, we evaluated the impact of EGFR status on patients' prognosis. Results: Among 68 primary glioblastoma patients, EGFR vIII was detected in 14.7% (10 cases); EGFR amplification (by FISH) was identified in 34% (23 cases); 75% (51 cases) showed EGFR overexpression. Of 13 EGFRvIII cases, 10 (76.9%) and 11 (84.6%) showed EGFR amplification by FISH and overexpression by IHC respectively. EGFR mutation showed significant correlation (p<0.01) with amplification, but not with overexpression. Nineteen (83%) out of 23 EGFR amplified primary glioblastoma cases showed EGFR overexpression (IHC 2+/3+), and among 51 EGFR overexpression (IHC 2+/3+) cases, EGFR amplification were identified in 19 (37%) cases by FISH. On survival analyses with 68 patients who underwent surgical resection, EGFR overexpression, amplification, or mutation shows no significant impact on patients' overall survival. Conclusions: We compared EGFR status in high grade gliomas and analyzed its prognostic value. A significant correlation between EGFR mutation and amplification was identified, and this finding correlates with previous studies. However, The EGFR status seemed to show no significant prognostic value in high grade glioma patients in this study.
SSTR2a Status and Response to Somatostatin Analogues for Acromegaly
Giselle Lopez, Lewis S Blevins, Arie Perry. University of California-San Francisco, San Francisco, CA. Background: Acromegaly due to pituitary adenoma is a clinically challenging disorder with potentially high morbidity. Complete resection is not always possible, so somatostatin analogues are frequently administered to regulate growth hormone levels, though it is difficult to predict response. Prior studies found that levels of somatostatin receptor 2a (SSTR2a) were decreased in tumors following pre-surgical treatment with somatostatin analogues (Casar-Borota 2013) supporting it as a key modulator of growth hormone release. Herein, we explore the feasibility of SSTR2a staining and hypothesize that expression levels predict response to somatostatin analogues in patients with subtotal tumor resection. Design: We identified 44 patients with growth-hormone positive pituitary adenomas and persistently elevated insulin-like growth factor levels following tumor resection, suggesting subtotal resection. We assessed the staining intensities of SSTR2a in tumor samples and correlated this data with therapeutic response in a subset. Results: Of 44 patients, 18% had negligible staining for SSTR2a in a minority of tumors cells, whereas 75% had strong intense staining in the majority of the cells. Less than 5% had intermediate staining for SSTR2a. Within a preliminary subset of nine patients with outcome data, we found that three of four (75%) patients with strong tumoral SSTR2a expression had complete or near complete response to the somatostatin analogue, whereas this was true of only one of five (20%) patients with weak tumoral staining. Conclusions: Based on our study, staining patterns for SSTR2a appears to be largely binary, with either strong staining in the majority of tumor cells, or weak staining in a small fraction. Preliminary data show a good correlation between staining pattern and response to treatment, supporting the hypothesis that degree of SSTR2a staining correlates with response to treatment with somatostatin analogues. Additional response data is being collected in the larger cohort. Background: Blood brain barrier (BBB) dysfunction has been postulated to play an early role in the pathogenesis of Alzheimer's disease (AD), the most common cause of dementia worldwide. Cerebral amyloid angiopathy (CAA), in which amyloid accumulates in arterioles and capillaries, is seen in the majority of patients with AD and may contribute to the compromise in BBB function. Design: To investigate the effects of CAA on BBB integrity, we evaluated the immunohistochemical expression of the endothelial marker CD31 and the basement membrane protein collagen IV, in the brains of AD subjects with varying degrees of CAA. Autopsy tissue from the occipital cortex, a region preferentially affected by CAA, from nineteen AD patients were categorized into subjects with arteriolar CAA, both arteriolar and capillary CAA, and without CAA. The intensity of staining was quantified using positive pixel counting, and the results were correlated with amyloid beta 1-40 and 1-42 immunoreactivity in vessels involved by CAA as well as degree of arteriosclerosis calculated by the arteriosclerotic index. Results: CD31 immunoreactivity was reduced in the brains of AD subjects with arteriolar and both arteriolar and capillary CAA compared to AD subjects without CAA (P = 0.03) while collagen IV deposition was more pronounced in patients with CAA than in those without (P = 0.002). There was no statistically significant difference in the arteriosclerotic index between the different groups.
Conclusions: Our results demonstrate a disruption of the BBB, suggesting degeneration of the endothelium and alteration of basement membrane components, in the brains of AD patients with CAA. A better understanding of the pathogenesis of CAA, an important substrate of dementia, may help shed light on mechanisms of neurodegeneration to facilitate the development of novel therapeutic approaches. The purpose of this study was to evaluate the correlation of morphological and molecular findings with outcome in a cohort of primary intraocular malignant melanomas (IOMM) in the Irish population. Design: All patients with IOMM who had an enucleation procedure were identified from institutional files in the Irish national referral centre over a 435 month period. The glass slides were reviewed by four histopathologists, and several morphological features were assessed. Molecular analysis and clinical follow-up was obtained where possible. Results: Over 435 months, 96 patients had a surgical excision of an IOMM. Histological material and clinical follow-up were available for 58 patients (average age: 56.6 years; M:F=1:1.5). The majority of patients (43.1%) had mixed tumor morphology. Nuclear pleomorphism was rare (12.1%). The average greatest tumor dimension was 13mm (11.5mm, 12.5mm and 16.6mm for spindle, mixed and epithelioid morphology, respectively). 29.3% of patients had metastatic disease, with the liver being the most common site of metastasis (8/17). 81.3% of these patients had mixed (43.8%) or epithelioid (37.5%) morphology, 25% had nuclear pleomorphism and 29.4% had tumour necrosis. The average greatest tumor dimension was 15.4mm (11.7mm in patients without metastasis). 15 patients died of disease (average length of time alive post-operatively: 62.1months). 85.7% of these patients had mixed (50%) or epithelioid (35.7%) tumor morphology, 21.4% had nuclear pleomorphism and 26.7% had tumor necrosis. The average greatest tumor dimension was 16mm (12.3mm in patients who did not die of disease). 41.7% (5/12) of patients tested had a molecular abnormality (monosomy 3 in all cases): 80% of these patients had mixed or epithelioid morphology, 40% had nuclear pleomorphism, 40% had an infiltrative border, the average greatest tumor dimension was 14.6mm and 25% had a metastasis. One case had a GNAQ Q209L mutation and another case had a GNA11 Q209L mutation.
Conclusions:
We report a series of IOMM in an Irish population, which is more prevalent in Ireland than in the United States. Tumor morphology, nuclear pleomorphism and tumor necrosis correlate well with poor prognosis in our cohort of patients. 
PD-L1 Expression in
Design: All patients with IOMM who had enucleation procedure were identified from institutional files in the Irish national referral center over a 435 month period (November 1974 -February 2011 . The pathology was reviewed in all cases. IHC for PD-L1 was performed in cases with little or no melanin pigment. PD-L1 expression was scored by two pathologists blinded to clinical outcomes: cytoplasmic and membranous staining was assigned a qualitative (weak, moderate and strong staining) and a quantitative (staining in <25%, 25-50% and >50% of tumour cells) score. Staining of PD-L1 in tumor infiltrating lymphocytes (TILs) was assessed. Results: A total of 96 patients had a surgical excision of an IOMM. Histological material and clinical follow-up were available for 58 patients (average age: 56.6 years; range: 36 -79; M:F 1:1.5). IHC with PD-L1 was performed on the archival material of 37 patients. Both cytoplasmic and membranous staining was present in 56.3% of mixed type (epithelioid and spindle) tumors and in 83.3% of epithelioid type tumors. The majority of spindle type tumors (66.7%) had predominantly cytoplasmic staining. Moderate to strong membranous staining in ≥25% of tumor cells was present in all of the epithelioid type tumors. PD-L1 staining of tumor infiltrating lymphocytes (TILs) was evaluated in five patients. In 80% of cases, TILs were positive for PD-L1: none of these cases had metastatic disease or died of disease. In 20% of cases, TILs were negative for PD-L1: this patient had metastatic disease and died of disease. Conclusions: Our results indicate that there is a correlation between the pattern of PD-L1 expression in tumor cells and tumor morphology, and between the pattern of PD-L1 expression in TILs and clinical outcome. . CIV deficiency is commonly associated with mitochondrial disorders. We hypothesize that low SSMA% is associated with CIV deficiency. We propose to establish that low SSMA% is a useful biomarker for CIV deficiency in muscle of children with suspected mitochondrial disorder. Design: This is a retrospective study of patients having open muscle biopsy (between Jan, 2009 -Jan, 2012) for suspected mitochondrial disease. Inclusion criteria were: age 0-18y; open biopsy of quadriceps muscle; neuropathological evaluation of muscle; and spectrophotometric analysis of ETC complex activities by a single reference lab. Exclusion criteria were: previous participation in any pathological research study; and confirmed diagnosis of muscle disease. ETC activities were normalized for citrate synthase (CS) activity. For detailed methods see Ref 1. Results: 106 patients, ranging in age from 2mo-18y (73 males), met the inclusion criteria. No biopsies were noted to have COX-negative or ragged-red myofibers on path exam. SSMA were observed and counted in 102/106 (96%) of biopsies. Four specimens had no SSMA. The median SSMA% was 4.0% (range 0-35%). The interquartile ranges for SSMA% study groups were: Gp1 ≤2.0%/hpf (N=28); Gp2 >2% to <10%/hpf (N=41); and Gp3 ≥10.0%/hpf (N=37). Significant differences between SSMA% groups were found for CIV CS (P=0.002), CS (P=0.026), and CII+III CS (P=0.026). CIV CS deficiency was 3.8 times more frequent in Gp1 than in Gp2 and Gp3 combined (P=0.05). Conclusions: By using more stringent inclusion criteria than in our previous study (Ref 1) , this study shows that pediatric muscle biopsies with low SSMA%, i.e. ≤2%/hpf, are significantly more likely to be associated with low CIV CS activity than in muscle with >2% SSMA/hpf. Thus, low SSMA ≤2%/hpf in muscle biopsy should be a useful biomarker for CIV deficiency in children with suspected mitochondrial disorders. Background: Pluripotent stem cells hold promise for the treatment of a wide variety of human diseases and are under active investigation in many animal models and human trials. However, some patients have pursued stem cell therapy in less regulated medical environments. The outcomes of such activity are generally not published and are poorly understood. We report the case of a 66 year old man with a history of left hemiplegia following a right middle cerebral artery infarction. In seeking regenerative treatment for hemiplegia, he reportedly received multiple off-label intrathecal and intraarterial injections of neural, mesenchymal, and embryonic stem cells. He subsequently presented with progressive lumbar pain, lower extremity paresis and anesthesia, and urinary incontinence and was found by radiologic imaging to have a diffusely enhancing mass process of uncertain origin involving the cauda equina and lumbar nerve roots.
Tumor-like Mass Arising as a Side Effect of Intrathecal Therapeutic Stem Cell Injections
Design:
We performed immunohistochemistry to identify the proliferation rate and differentiation pathway of the lesion. We also performed short tandem repeat (STR) genotyping analysis to assess the origin of the lesional cells. Additionally, we performed targeted exome sequencing of the lesion for mutations in 309 cancer-causing genes. Results: Neurosurgical biopsy of the spinal cord lesion and H&E analysis revealed a densely cellular lesion encasing the spinal cord and nerve roots with moderate atypia and some features of a neoplasm with evidence for glial differentiation. Immunohistochemistry showed lesional cells expressed SOX2, OLIG2, and GFAP, along with elevated MIB-1, indicating a highly proliferative glial lesion, with pathologic features overlapping with a high grade glioma. STR genotyping demonstrated the majority of cells (62%) to be of non-patient origin. No mutations were identified among the 309 genes sequenced. Conclusions: We report the case of a 66 year old male in which injected therapeutic stem cells developed into a rapidly proliferative and symptomatic glial tumor. While stem cell therapy holds the potential to transform treatment of many conditions, unintended complications can occur. Our finding of an aggressive high grade exogenous tumor in this patient identifies a devastating potential complication of stem cell therapy, underscoring the need for thorough evaluation of safety and efficacy in developing new medical therapies. required for successful sequencing of 100% frozen and 96% formalin-fixed, paraffinembedded tissue specimens, including small biopsy specimens. The assay sensitivity was 3-5% of mutant alleles for SNVs and 1-5% for gene fusions. The most commonly detected alterations were IDH1, TP53, TERT, ATRX, CDKN2A, and PTEN in high-grade gliomas, followed by BRAF fusions in low-grade and H3F3A mutations in pediatric gliomas. The cost of GlioSeq reagents was 15 times less than the combined cost of individual tests performed by conventional techniques. Conclusions: GlioSeq NGS assay offers accurate and sensitive detection of a wide range of genetic alterations in a single workflow. It can be performed on FFPE resected tumor specimens and small biopsy specimens. It allows for rapid and cost-effective profiling of brain tumors assisting with tumor diagnosis and providing valuable information for patient management.
Chronic Traumatic Encephalopathy-Like Abnormalities in a Routine
Neuropathology Service Shawna Noy, Sherry Krawitz, Marc Del Bigio. University of Manitoba, Winnipeg, MB, Canada. Background: Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease characterized by the widespread deposition of hyperphosphorylated tau in cortical regions of the brain. Occurring after repetitive mild head injury, it has been described in professional athletes and military veterans. It is important to know whether this disorder may occur in other individuals as well. The purpose of this study is to describe the features and occurrence of CTE-like pathological changes in a routine neuropathology service. Design: From autopsies on individuals aged 18-60 years, we examined the brains retained for neuropathological examination between July 2013 and December 2014. Those with findings diagnostic of other neurodegenerative diseases were excluded from the study. Sections of brain were sampled to include the paramedian frontal, lateral frontal, medial temporal lobe including amygdala, and hippocampus with adjacent temporal lobe. Slides from formalin-fixed paraffin-embedded tissue were stained with hyperphosphorylated tau immunostain. The presence or absence of tau-immunoreactive deposits in a CTE-like distribution (multiple cell types and neuropil in a perivascular or deep sulcus) was evaluated by two senior neuropathologists along with a pathology resident. If present, the distribution was graded using the CTE grading scheme outlined by McKee et al. 2013 . CTE stages were then correlated with the patients' available medical history, specifically noting any evidence of previous head injury. Results: Among the 101 brains examined, 64/101 were negative for CTE-like changes; 27/101 were CTE stage < 1; 7/101 were CTE stage 1; 2/101 were CTE stage 2; and 1/101 was CTE stage 3. A history of previous head injury was present in all CTE stage 2 and 3 cases and 5/7 CTE stage 1 cases. Prior head injury was found to be associated with CTE-like changes (Chi square, p<0.002), but a history of alcohol/drug abuse was not (p=0.114).
Conclusions:
In addition to the expected findings in head-injured individuals, CTE-like changes were also occasionally seen in individuals without a known history of head injury. Limitations of the study include: bias in autopsy referral pattern, incomplete historical information, and variable number of sections studied. The optimal number of brain regions to be sampled in order to make a diagnosis of CTE remains to be determined. In addition, grading as per McKee et al. 2013 was difficult to transpose owing to a difference in methodology. Consensus grading schemes applicable to a neuropathologist's routine practice should be a focus of future study. Michael Paolini, Benjamin R Kipp, William R Sukov, Aditya Raghunathan, Emily G Barr Fritcher, Derick M Aranda, Karen SantaCruz, Sadeq Al-Dandan, Pete Fisher, William McDonald, Charles P Bondurant, Grant Van Dyke Darkow, Caterina Giannini, Joseph E Parisi, Mark E Jentoft. Mayo Clinic, Rochester, MN; Northwestern University, Chicago, IL; University of New Mexico, Albuquerque, NM; King Fahad Medical City, Riyadh, Saudi Arabia; North Valley Hospital, Kalispell, MT; Abbott Northwestern Hospital, Minneapolis, MN; Boone Hospital Center, Columbia, MO. Background: Atypical Teratoid/Rhabdoid Tumors (AT/RTs) are uncommon neoplasms of the CNS that typically arise in the posterior fossa of children less than two years old. Rare sellar-region examples have been described in eight adult women. AT/RT is characterized by high-grade histologic features and loss of SMARCB1 (also known as INI1) expression. Design: Five cases of sellar ATRT, seen in consultation at our institution since 2013, are described with genetic characterization and clinical follow up. All cases were assessed for genetic alterations using a next generation sequencing (NGS) 50 gene, "CNS centered" tumor panel, as well as OncoScan arrays to detect copy number variants and loss of heterozygosity. Results: All five patients were women (ages 31 -65 years) who presented with a symptomatic intrasellar mass with suprasellar extension in two cases. Visual disturbances, such as diplopia or decreased acuity, were reported in the three cases where presenting symptoms are known. Extent of surgical resection was subtotal in four (unknown in one). Microscopically, the tumors demonstrated high-grade/poorlydifferentiated histopathologic features and loss of SMARCB1 expression. Two patients died without further treatment, one in the immediate postoperative period and one at day 51. Three patients received both radiation and chemotherapy and are alive with stable disease at 262, 363 and 675 days. Three tumors had pathogenic mutations of the SMARCB1 gene detected by NGS (two nonsense mutations and one frameshift) while the remaining two showed large deletions of the SMARCB1 locus. No other significant genomic alterations were detected. Conclusions: Sellar AT/RT is a rare tumor that requires consideration in adult women presenting with a sellar-region mass. Although some cases may show response to radiation and chemotherapy, experience with this entity is necessarily limited and further analysis is required to determine if adult sellar AT/RT warrants characterization as a distinct entity.
Atypical Teratoid/Rhabdoid Tumors (AT/RTs) of the Sellar Region in Adults: Characterization of Five Cases
Molecularly Defined Adult Gliomas with Known ATRX Status: Does TERT Have an Additional Prognostic Role
Melike Pekmezci, Kyle M Walsh, Annette Molinaro, Paul A Decker, Helen M Hansen, Hugues Sicotto, Terri Rice, Tom Kollmeyer, Lucie McCoy, Gobinda Sarkar, Alissa A Caron, Arie Perry, Caterina Giannini, Tarik Tihan, Mitchel S Berger, Joseph Wiemels, Jeanette Eckel-Passow, Dan Lachance, John Wiencke, Robert B Jenkins, Margaret Wrensch. University of California San Francisco, San Francisco, CA. Background: Previous literature indicates that molecularly defined glioma subgroups have a prognostic role in the management of adult glioma patients. Proposed subgroups commonly include some combination of IDH, 1p19q codeletion and tumor's telomere maintenance strategy, defined by mutations in either TERT or ATRX. The roles of IDH and 1p19q are well-accepted and ATRX has been adopted in some neuropathology practices. ATRX immunohistochemistry findings were part of ISN-Haarlem guidelines. To determine whether ATRX and TERT mutation status provide different prognostic information, we analyzed the additional prognostic role of TERT in glioma patients already defined by their IDH, ATRX and 1p19q status. Design: We analyzed molecular features of 1149 infiltrative adult gliomas (Grades II-IV) from the UCSF Adult Glioma Study, The Mayo Clinic, and TCGA using a combination of immunohistochemistry, FISH and sequencing, and evaluated their effects on prognosis as measured by overall survival. Results: Among 601 IDHmut glioma patients, 323 with ATRXmut gliomas had significantly worse survival than those who had ATRXwt gliomas. Among 278 patients with IDHmut/ATRXwt gliomas, 215 with 1p19q-codel gliomas had significantly better survival than those with 1p19q-intact gliomas. Among patients with IDHmut/ ATRXwt/1p19q-codel gliomas, 197 with TERTmut gliomas had a significantly better survival. Among patients with IDHmut/ATRXwt/1p19q-intact gliomas, 19 with TERTmut gliomas did not show a significant difference in survival compared to 44 with TERTwt gliomas, though statistical power was lacking for this comparison. Among 548 patients with IDHwt gliomas, the 30 with ATRXmut gliomas had significantly better survival than those with ATRXwt gliomas. Furthermore, among those with IDHwt/ATRXwt gliomas, 417 with TERTmut gliomas, representing "primary glioblastomas," had a worse prognosis than those with TERTwt gliomas. Conclusions: These data indicate that TERT mutation status provides additional prognostic data among those with ATRXwt gliomas, irrespective of IDH status. This suggests that ATRX and TERT are complementary molecular markers which provide non-redundant information.
Expression of Nuclear Receptor NR4A3 in Multiple System Atrophy and Dementia With Lewy Bodies
Itzel Pineda, Nancy Edwards, David Goldstein, Abhik Ray-Chaudhury. NINDS, NIH, Bethesda, MD. Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disease that affects multiple brain regions and characterized by distinctive Glial Cytoplasmic Inclusions (GCI) composed mostly of alpha-synuclein (α-synuclein) protein, predominantly within the oligodendrocytes. Dementia with Lewy Bodies (DLB) is the second most common type of progressive dementia characterized by cortical and brainstem neuronal inclusions called Lewy Bodies that are composed of α-synuclein protein. Recent studies have found that nuclear receptor subfamily 4, group A, member 3 (NR4A3) accumulates specifically within neurons in DLB as well as in glial cells in MSA. NR4A3 plays a central regulatory role in cell proliferation, differentiation, metabolism and apoptosis. Design: In this study, several sections from pertinent regions of autopsied brains from patients (one each) with MSA and DLB were stained immunohistochemically with antibodies against α-synuclein and NR4A3 proteins that were reviewed and expressions of the proteins were compared. Results: In MSA, NR4A3 expression within oligodendrocytes was identified and matches the pattern of α-synuclein expression within GCIs. Most prominent expression was found in the cerebellum, basal ganglia (putamen and globus pallidus) and midbrain. In DLB, Lewy bodies were detected by α-synuclein and NR4A3 proteins in pigmented neurons of the midbrain (substantia nigra), Pons (locus ceruleus) and within the cortical neurons. NR4A3 expression was significantly increased in disease affected regions of the DLB and MSA brains, in comparison to the controls. Conclusions: In conclusion, the increasing evidence may indicate that accumulation of NR4A3 is specific to αlpha synucleinopathy and the function of NR4A3 appears to be etiologically linked with MSA and DLB; providing new knowledge in understanding the mechanism in the pathogenesis of of alpha synucleinopathies.
Molecular Characterization of 52 Glioblastomas in Young Adult Patients
Helene Plouhinec, Blandine Boisselier, Quentin Breton, Sophie Michalak, Philippe Menei, Philippe Guardiola, Audrey Rousseau. Angers University Hospital, Angers, France. Background: Glioblastomas (GB) are the most common and most aggressive primitive CNS tumors. When GB occur in the natural history of diffuse low-grade glioma, they are called "secondary", and GB occurring without past history of diffuse glioma are known as "primary". The latter represent 95% of adult GB, with a mean age at diagnosis of 62 years and EGFR amplification in 40% cases. Secondary GB, occurring in younger patients (40-45 years), are characterized by IDH1/2 mutations. Recurrent mutations of histones H3 were recently identified in pediatric (PD) GB. GB in young adults (20-40 years), because of their rarity, have been seldom studied. They could be related to conventional GB in the elderly (EGFR amplification) or to PD GB (H3 mutation). They could also be secondary GB (IDH mutation) even in the absence of past history. Finally, they could develop along yet to discover gliomagenesis pathways. Design: The main objective of this work was the molecular characterization of 52 young adult GB (18-40 years). Immunohistochemistry for histone H3K27me3, IDH1-R132H, ATRX, and p53 was performed. H3.3/H3.1, IDH1/2, ATRX, TP53, and pTERT genes were sequenced by Sanger and NGS techniques. Whole genome SNP array was performed on 25 GB, and FISH for EGFR status was done on another 11 cases. Results: 10% of patients harbored H3 mutation (PD GB), with age at diagnosis < 30 years and survival < 1 year. 27% of patients had IDH mutation; age at diagnosis was between 30 and 35 years, and overall survival was 15 months. 13% of clinically de novo GB were in fact genetically secondary (IDH mutation). 45% of cases without IDH or H3 mutation showed genomic profiles typical of elderly GB (including EGFR amplification in 60% cases and pTERT mutation in 66% cases); age at diagnosis was > 35 years and overall survival was 12 months. 11.5% of 52 GB had no specific genetic alteration (IDH/ H3 mutation or EGFR amplification), except for BRAF-V600E mutation in one case. Conclusions: Molecular characterization of young adult GB is of tremendous importance since targeted therapies against mutated protein IDH1/2 or histone H3 are already underway and will hopefully dramatically change the management of these young patients. Elderly-type GB may have some predisposing factors to cancer. In GB with no genetic alteration of the "usual suspects" (IDH, H3, EGFR), alternative pathways of gliomagenesis are most likely involved. Background: Tethered cord syndrome (TCS) is characterized by clinical symptoms of lower extremity weakness, altered gait, parasthesia, pain, and urinary symptoms that result from traction of the terminal end of the spinal cord (filum terminale). Occult tethered cord syndrome (OTCS) is a newly recognized clinical variant that lacks the classic radiologic features of TCS and is associated with predominantly urinary symptoms and pain in both pediatric and adult populations. Current understanding of the pathophysiology and treatment of OTCS is limited and differs from traditional TCS. Structural changes involving increased adipose tissue, collagen and elastic fibers in the filum terminale may be responsible for OTCS. Inflammatory changes, including mast cell activation within the filum may also play a role. OTCS also appears to be common in patients with Ehlers Danlos syndrome (EDS) for unknown reasons. To provide further insight into the role of inflammatory mediators and structural abnormalities in OTCS we performed a thorough examination of the tissues removed from these patients at the time of surgery. Design: 12 cases of OTCS, including 5 cases of EDS were collected after surgical intervention. All samples were processed for histochemical, immunohistochemical, and electron microscopic (EM) evaluation. Slides were examined and analyzed for vascularity, adipose tissue content, and presence or absence of inflammation. Trichrome and elastin stains were performed to assess collagen and elastic fiber content, Toluidine blue and CD117stains were utilized for mast cell identification. Other stains included CD45 for lymphocytes and CD68 for macrophages. EM analyses were performed to assess collagen and elastic fiber ultrastructural organization. Results: Minimal inflammation was present in nearly all filum samples examined, however, mast cells were found to be common in patients with EDS. Increased vascularity and reduced elastic fiber content were also noted in EDS patients. Electron microscopic findings showed subtle evidence of collagen thickening and disorganization. Conclusions: Mast cell activation, increased collagen, and decreased elastic fiber content were common among OTCS patients with EDS. These observations may provide clues about the pathophysiology of this rare and newly recognized disorder. Michael Punsoni, Kara A Lombardo, Shamlal Mangray, Edward G Stopa, Evgeny Yakirevich. Brown University and Rhode Island Hospital, Providence, RI. Background: Succinate dehydrogenase (SDH) is a key mitochondrial enzyme complex composed of 4 subunits. SDH histochemical staining is routinely utilized in the assessment of muscle biopsies to reveal underlying pathology such as abnormal subsarcolemmal mitochondrial aggregates. A monoclonal antibody (MAb) that recognizes the SDHB subunit in formalin fixed paraffin embedded (FFPE) tissues has recently become available. In this study we evaluated the utility of SDHB immunohistochemistry (IHC) in diagnosing neuromuscular diseases. Design: 29 muscle biopsies, including 14 mitochondrial myopathies (MMs), 5 polymyositis, 5 dermatomyositis, and 5 controls (NM) were evaluated. SDHB IHC was performed on FFPE tissue sections using a mouse MAb (Abcam 21A11AE7) at 1:200 dilution. Histochemical SDH stains were performed on fresh-frozen tissue. The pattern of staining was evaluated by light microscopy. Mitochondrial number, size, and organization were also assessed by electron microscopy (EM) in MM cases. Results: In all muscle biopsies SDHB IHC exhibited granular immunoreactivity and clearly highlighted the dark type I and lighter type II staining pattern observed using histochemistry. Unlike SDH histochemistry, sarcomeric cross-striations were also clearly evident on SDHB IHC. Cases of MM SDHB IHC exhibited subsarcolemmal granular aggregates that were more distinct than those seen by SDH histochemistry ( figure 1a) . In six cases of MM variably-sized SDHB immunoreactive aggregates filled the entire fiber (figure 1b). Subsarcolemmal and cytoplasmic aggregates on SDHB immunostain correlated with mitochondrial pathology on EM. In cases of inflammatory myopathy, there was diffuse sarcoplasmic SDHB immunoreactivity noted in degenerating fibers but no evidence of subsarcolemmal aggregates.
Succinate Dehydrogenase B (SDHB) Immunohistochemistry Is an Effective Alternative to SDH Histochemistry in the Evaluation of Muscle Biopsies
Conclusions: SDHB IHC was highly sensitive and highly specific in the identification of MM and exhibited fiber-typing identical to histochemical staining. The automation, reproducibility, and cost efficiency of SDHB IHC offer advantages over the labor intensive histochemical method requiring frozen sections. This technique works well on FFPE tissues and can be easily used to perform retrospective archival studies. TM chips on an Ion Torrent PGM instrument. Results: Four of the 5 anaplastic ependymomas with successful DNA extraction were located intra-cranially and occurred exclusively in pediatric patients (age < 18). Five of the grade II ependymomas were located in the spinal cord. The NGS analysis detected pathogenic gene mutations in one of 4 anaplastic ependymomas (25%) and four of 11 grade II ependymomas (36%). The patients with grade II ependymomas have a significantly better 5-year event free survival rate (EFS) and a relatively longer 5-year overall survival (OS) compared to those with grade III ependymomas. Multiple pathogenic gene mutations were detected in two ependymomas of pediatric patients, one each in grade II and III. The PDGFRA and SMO genes carrying pathogenic and likelypathogenic mutations were commonly mutated in both grade II and III ependymomas, suggesting a potentially important mechanism of progression in pediatric patients through the activation of PDGFRA and sonic hedgehog pathways. Conclusions: From the current study, we found that pediatric patients tend to have a higher grade ependymomas (anaplastic) which more often occurred intra-cranially. Ependymomas occurring in pediatric patients were more likely to have multiple pathogenic gene mutations. The patients with the grade II ependymomas have a significantly better 5-year EFS compared to those with grade III ependymomas and a relatively longer 5-year OS. A greater sample size is needed to further elucidate the specific molecular events responsible for tumorigenesis and progression of ependymomas.
Mutational Profiling of Ependymomas by Next-Generation
Combinatorial Targeted Next-Generation Sequencing and Cytogenetic Microarray Profiling Identify Novel Molecular Mutations in Uveal Melanoma
James Solomon, David Brown, Frances Wu, Marie dell'Aquila, John A Thorson, Jonathan H Lin. University of California, San Diego, San Diego, CA. Background: Uveal melanoma is the most common primary intraocular malignancy in adults and has a strong propensity to hematogenously metastasize to the liver. The molecular pathways of tumorigenesis for uveal melanoma are distinct from cutaneous melanoma, and therefore many of the targeted molecular therapies for cutaneous melanoma are ineffective in uveal melanoma. Recently, panels of genetic markers have been used to stratify tumors into different prognostic groups, but thorough understanding of the molecular tumor biology of uveal melanoma lags behind many other tumors. Here, we apply next-generation sequencing and cytogenetic microarray profiling to further understand the molecular biology of uveal melanoma and identify potentially novel mutations. Design: Uveal melanoma enucleation and biopsy specimens from 12 patients at a single institution were collected from 2012 to 2015. On all specimens, DNA was extracted from unstained tissue sections, and a targeted next-generation sequencing assay that examines 397 cancer-related genes was performed. After alignment, bioinformatic analysis, and removing silent, benign, and germline mutations, the remaining mutations were classified as either clinically significant or mutations of unknown significance. A subset of the specimens also had genetic profiling at an outside institution or genome-wide SNP-based microarray analysis to characterize copy number abnormalities performed. Results: Clinically significant mutations were identified in all specimens. A mutation in either GNAQ or GNA11 at codon Q209 was seen in every specimen. In addition, mutations in SF3B1 (p.R625H) were seen in 33% of cases. BAP1 premature termination mutations, associated with poor prognosis, were seen in two specimens, with a third showing loss of heterozygosity at the BAP1 locus by microarray. EIF1AX exon 1 and 2 mutations were identified in two cases. Finally, novel mutations in the CDKN2A/B, KAT6B, SMAD4, ESR1, and PBRM1 cancer genes were identified in one to two cases each. Conclusions: Many of the mutations identified in our study, including GNAQ, GNA11, SF3B1, BAP1, and EIF1AX, have been previously found to be associated with uveal melanoma, and our case series serves to strengthen these associations. In addition, our research identified several novel mutations in CDKN2A/B, KAT6B, SMAD4, ESR1, and PBRM1. The clinical significance of these novel mutations in uveal melanomas is unknown and deserves additional study. The biological mechanism and potential effects of all identified mutations are discussed. Background: An estimated 15-80% of patients receiving chemotherapy develop cognitive deficits, particularly in executive function. The pathophysiology underlying this "chemobrain" phenomenon is poorly understood. Based on animal studies, oxidative stress appears to play a role, and chemotherapy patients are reported to have elevated serum markers of oxidative stress. Oxidative stress, which might be mediated in part by microglia, has also been linked to neuronal loss of heterochromatin, resulting in aberrant gene expression and cell death. This is the first reported study describing cellular and molecular alterations in human brain tissue after chemotherapy treatment. Design: Sections of formalin-fixed, paraffin-embedded frontal cortex from 3 cohorts --cancer patients treated with chemotherapy (n=10), cancer patients treated with surgery (n=8), and patients without history of cancer (n=11) --were stained with H3K9me2, nitrotyrosine, and CD68 staining to assess for heterochromatin chromocenters, oxidative stress, and presence of activated microglia. An unpaired student's t-test was used when making comparisons between cohorts. Results: The chemotherapy cohort had a higher percentage of nitrotyrosinepositive neurons (60.1%) than the surgery and negative cancer cohorts (50.7% and 51.2%, respectively; p<0.001) and decreased neuronal H3K9me2 heterochromatin chromocenter staining (32.6% positive) compared to the surgery and negative cancer cohorts (41.1% and 43.4%, respectively; p<0.001). Chromocenter assessment with DAPI confirmed loss of heterochromatin in the chemotherapy cohort compared to the negative cancer cohort. The percentage of microglia that were activated was increased in the chemotherapy cohort (68.9%) compared to the other cohorts (surgery: 54.0%, negative cancer: 51.1%; p<0.02). Finally, within the negative cancer group, there was a trend towards increased oxidative stress, decreased heterochromatin, and higher proportion of activated microglia with aging. Conclusions: There is an association between elevated oxidative stress, loss of heterochromatin, and activated microglia in the frontal cortex of chemotherapy patients, raising the possibility that these changes have an important mechanistic role in the pathophysiology underlying chemotherapy related cognitive impairment. The data also suggest that chemobrain might be a paradigm of accelerated aging. -methylguanine-DNA methyltransferase, a DNA repair gene) by promoter hypermethylation is associated with improved outcomes in GBM patients receiving temozolomide (an alkylating agent). The methylation status of the MGMT promoter is most commonly assayed by methylationspecific PCR (MSP). MSP, however, is a technically challenging qualitative assay with poor precision. Accordingly, MSP is performed on multiple aliquots of DNA from each GBM sample, leading to three possible results: methylated, unmethylated, and partially methylated. A partially methylated result is reported when the methylated product is seen in some, but not all, aliquots from a single GBM sample. The prognosis for GBM patients with partially methylated results has not been established. Design: All MGMT promoter methylation tests performed at the Center for Advanced Molecular Diagnostics (Brigham and Women's Hospital, Boston, MA) between 2009 and 2012 were retrospectively reviewed. MGMT test results (methylated, partially methylated, or unmethylated) were correlated with neuropathology diagnoses and clinical follow-up data through institutional electronic records. Kaplan Meier survival analyses (using R, version 3.2.2) were performed on patients diagnosed with WHO Grade IV gliomas and with clinical follow-up data. Results: 1025 MGMT results were reviewed. 377 of these (147 methylated, 53 partially methylated, and 177 unmethylated) were included for survival analyses. For WHO Grade IV gliomas, the partially methylated cases (red; 53/377 = 14% of our dataset) had similar overall survival compared to unmethylated cases (green; p = 0.40), and shorter survival compared to methylated cases (black; p = 0.020, see Figure) .
MGMT Promoter Methylation Status and Overall Survival in Glioblastoma Patients
Conclusions:
Partially methylated results are not uncommon in MGMT MSP testing (14% in this review), and the corresponding tumors behave clinically like unmethylated tumors. This study suggests that replicate MSP testing of all GBM samples is warranted, to distinguish partially methylated cases from methylated cases with better outcomes.
Histopathologic Features of Peripheral Nerve Sheath Tumors Involving the Eye and Ocular Adnexa
Mingjuan L Zhang, Maria J Suarez, Fausto Rodriguez. Johns Hopkins University School of Medicine, Baltimore, MD. Background: Peripheral nerve sheath tumors (PNSTs) are known to occur in the ocular adnexa and orbit and comprise 4% of all orbital tumors, but have not been well-studied in contemporary literature. Design: 93 specimens from 68 patients were identified from an institutional database search for PNSTs involving the eye and ocular adnexa . Results: The mean age was 32.5 years. Locations included orbit (50.5%), eyelid (46.2%) and other ocular adnexa [table 1]. The majority of specimens were neurofibromas (67.7%), followed by schwannomas (11.8%) and neuromas (10.8%). 56 (88.9%) of the neurofibroma cases were neurofibromatosis 1 (NF1)-associated. Among neurofibromas, 31.7% were conventional, 38.1% were plexiform, 25.4% were diffuse, and 4.8% were diffuse and plexiform. Tumors involved skin (31.7%), soft tissue (11.1%), skeletal muscle (22.2%), peripheral nerve (63.0%), lacrimal gland (20.6%) and choroid (n=1). Other histologic findings included pseudo-Meissner corpuscles (27%), Schwann cell nodules (4.8%), prominent myxoid component (7.9%), melanin-like pigment (3.2%), and inflammation (14.3%). Available immunostains included S100 (+ in 15/15 cases), EMA (+ in 2/4 cases), CD34 (+ in 4/4 cases), and Ki67 (<1% in 4/4 cases). Focusing on schwannomas, 81.8% were conventional and 18.2% were plexiform. Observed features included a capsule (45.5%), hyalinized vessels (45.5%), Verocay bodies (63.6%), and Antoni B pattern (45.5%). Immunostaining included S100+ in 4/4 cases, collagen IV+ and Ki67<1% in 3/3 cases. Conclusions: Neurofibromas are the most common PNST involving the eye and ocular adnexa and the majority are associated with NF1. A plexiform pattern and the presence of pseudo-Meissner corpuscles are relatively frequent at this site. Background: A blind painful eye (BPE) is the end stage clinical diagnosis of several ocular diseases, including inflammatory, vascular, and glaucomatous conditions. The morphological findings that can be encountered are broad and often related to the original condition. The aim of this study is to document the frequency of the most common morphological features in BPE by topographical location. Design: In total, 167 cases clinically diagnosed with BPE over a 21-year period were reviewed. The cases were categorized as enucleations (54.5%) and eviscerations (44.5%). The morphological findings were subdivided accordingly to each topographic intraocular location. Results: Mean age at diagnosis was 55.6 years (1-88) with equal sex distribution. In enucleation and evisceration specimens, the two most common findings in each topographic location were as follows (respectively): in the cornea, chronic keratitis with neovascularization (78%/85.3%) and subepithelial pannus (22%/30.7%); in the iris, anterior synechia (35.2%/17%) and rubeosis iridis (12,1/not applicable [NA] ); in the trabecular meshwork, angle closure glaucoma (44%/NA); in the anterior chamber, epithelial ingrowth (3.3%/NA); in the lens, cataract (20.9%/24%); in the retina, retinal detachment (67%/NA) and retinal gliosis (64.8%/77.3%); in the choroid, nongranulomatous uveitis (44%/66.7%); and for optic nerve, optic nerve atrophy (45%/ NA). Important diagnoses included two cases consistent with sympathetic ophthalmia, two Fuch's adenomas, and one toxoplasmosis case. Phthisical eyes were diagnosed by osseous metaplasia or shrunken eyes (<16 mm in diameter) and represented 23.9% of all enucleations. Conclusions: To the best of our knowledge, this is the first topographic study of blind painful eyes describing the histopathological features. Pathological evaluation of blind painful eyes is mainly used to rule out symphathetic ophthalmia, neoplasias, and infections, but there are also other subtle findings that may be useful to confirm the underlying clinical condition. Pablo Zoroquiain, Sultan Aldrees, Mohammed Qutub, Patrick Logan, Leonardo Dias, Miguel N Burnier. Mcgill University, Montreal, QC, Canada. Background: Primary carcinomas with apocrine differentiation (CAD) are infrequent tumors with several subtypes, including apocrine adenocarcinomas (AAs), extramammary Paget's disease, adenoid cystic carcinoma, and mucinous carcinoma (MC) among others. The purpose of this study is to describe the clinical and pathological characteristics of CAD in order to assist with differential diagnoses. Design: We reviewed 5,453 cases diagnosed at the Henry C. Witelson Ocular Pathology Laboratory, Montreal, Quebec over an 8-year period. Clinical and pathological data of all CAD diagnosed during this period were retrieved. Descriptive analysis, including frequency, size, location, gender, and age, was performed. Results: Of the 5,453 specimens reviewed, 3,014 (55.3%) cases were eyelid lesions. Five CAD cases were identified. Two cases were AAs and three cases MC (0.07% and 0.17% of the eyelid lesions, respectively). The AAs were diagnosed in a 59-year-old male and an 81-year-old female in the lower and upper eyelid, respectively. Both were clinically diagnosed as chalazions. Average lesion size was 4 mm and both cases showed luminal border decapitation and eosinophilic cytoplasm. One carcinoma was well demarcated with high pleomorphism, while the other showed infiltrative borders and bland cytological features. After 2 and 3 years of follow-up, respectively, no recurrences were seen. The MCs were diagnosed in three males (61, 88, and 84 years) with an average size of 10 mm. Two of them occurred in the lower eyelid. They were all clinically diagnosed as cystic basal cell carcinoma. All of them were characterized by mucin pools separated by thin fibrous septa with nests of cribiform cells. In one case, an intraepithelial component was seen favoring the primary nature of the lesion. One patient experienced local recurrence after 6 years of follow-up. Conclusions: To the best of our knowledge, this is the first comprehensive review of CAD of the eylid from a single institution. CAD are exceedingly rare low-grade malignant tumors with the potential for recurrence. The morphological spectrum of CAD is broad. Chalazion was the clinical misdiagnosis in all AAs, while MCs were misdiagnosed as cystic basal cell carcinomas. Identifying the intraepithelial portion of MCs may aid in the differential diagnosis of metastatic tumors. We encourage surgeons to submit all chalazions for pathological diagnosis due to the possibility that they may be malignant lesions.
Malignant Apocrine Tumors of the Eyelid in a Review of 5,453 Specimens
